Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | KDM4A | O75164 | 9/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120096 | 0.85 | CA2 (0.50) | ALDH1A1TSHRCA12CA2CA3 | |
| SCHEMBL3051346 | 0.84 | KDM5A (0.42) | KDM4CKDM5ACA12CA2CA9 | |
| SCHEMBL3047656 | 0.82 | CHRM2 (0.56) | — | |
| SCHEMBL8023238 | 0.81 | ALDH1A1 (0.41) | ALDH1A1DNM1KDM4AKDM4CKDM5A | |
| SCHEMBL3050142 | 0.80 | SIGMAR1 (0.36) | ALDH1A1KDM4CKDM5ASIGMAR1 | |
| SCHEMBL3046229 | 0.79 | KDM5A (0.38) | KDM4CKDM5A | |
| SCHEMBL3053086 | 0.79 | CHRM2 (0.46) | — | |
| SCHEMBL3054596 | 0.79 | KDM4A (0.35) | KDM4AKDM4C | |
| SCHEMBL3045288 | 0.79 | MEN1 (0.33) | — | |
| SCHEMBL3046271 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | claimed |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | VISKOV CHRISTIAN | 2010-07-08 | — | — | US | disclosed |
| US-7678766-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2010-03-16 | — | — | US | disclosed |
| EP-1098903-B1 | METHOD FOR PREPARING CYCLOSPORIN DERIVATIVES | AVENTIS PHARMA SA (FR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. | 2007-09-13 | — | — | US | disclosed |
| US-7226905-B2 | Process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2007-06-05 | — | — | US | disclosed |
| EP-0979244-B1 | NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2005-03-02 | — | — | EP | disclosed |
| EP-1040121-B1 | NOVEL METHOD FOR PREPARING CYLOSPORIN DERIVATIVES | AVENTIS PHARMA (FR) | 2004-07-21 | — | — | EP | disclosed |
| EP-0948527-B1 | CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2002-06-05 | — | — | EP | disclosed |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | AVENTIS PHARMA S.A. (FR) | 2001-09-27 | — | — | US | disclosed |
| EP-0951474-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1999-10-27 | — | — | EP | disclosed |
| WO-1998028330-A1 | NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213260-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | ALDH1A1 4617/4885TSHR 4710/4885DNM1 3460/4885 |
| US-20010025025-A1 | Novel process for the preparation of cyclosporin derivatives | MGMT, MALT1, TET2 | ALDH1A1 4617/4885TSHR 4710/4885DNM1 3460/4885 |
| US-20100173838-A1 | NOVEL PROCESS FOR THE PREPARATION OF CYCLOSPORIN DERIVATIVES | MGMT, MALT1, CHP1 | ALDH1A1 4507/4885TSHR 4706/4885DNM1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.